RxDoctor Payments DataLook up a doctor →

Hillary Bownik, MD

Gastroenterology · Kansas City, MONPI 1013147206

Payments from drug & device makers

$414,100in general payments, 2019–2025

Across 346 payments — averaging $1196.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$315K
  • Johnson & Johnson$38K
  • Janssen Scientific Affairs, LLC$26K
  • Takeda Pharmaceuticals U.S.A., Inc.$21K
  • AbbVie$8K
  • Amgen$2K
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$3,1254%
  • Speaking & faculty fees$71,72385%
  • Travel & lodging$2,5733%
  • Food & beverage$7,1048%
  • Education$400%
  • Entertainment$820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414,100 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$1,356,523
Medicare patients
559
Services billed
61,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab61$1,888,477
Humira(Cf) PenAdalimumab60$606,111
GattexTeduglutide12$556,290
CreonLipase/Protease/Amylase20$92,890
RinvoqUpadacitinib11$74,951
ZenpepLipase/Protease/Amylase18$69,698
XifaxanRifaximin11$24,929
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates263$17,232
LinzessLinaclotide16$10,784
TrulancePlecanatide12$6,665
Mesalamine16$6,189
Pantoprazole Sodium257$3,508
Budesonide EcBudesonide22$3,002
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,787
Balsalazide Disodium14$2,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$38,025$1,888,47761 claims
Takeda Pharmaceuticals U.S.A., Inc.Gattex$21,179$556,29012 claims
AbbVieCreon, Rinvoq, Linzess$8,224$178,62447 claims
Aimmune Therapeutics, Inc.Zenpep$39$69,69818 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$14$31,59323 claims
Fresenius Kabi USA, LLCSodium Chloride$85$3612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →